A5059435501- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Immunodeficiency and Autoimmune Disorders
- Gut microbiota and health
- Genetic Associations and Epidemiology
- Biosimilars and Bioanalytical Methods
- IL-33, ST2, and ILC Pathways
- Autoimmune and Inflammatory Disorders
- Autoimmune and Inflammatory Disorders Research
- Celiac Disease Research and Management
- Liver Diseases and Immunity
- Chronic Lymphocytic Leukemia Research
- Digestive system and related health
- Cytokine Signaling Pathways and Interactions
- RNA modifications and cancer
- Systemic Lupus Erythematosus Research
- Colorectal Cancer Treatments and Studies
- Diet and metabolism studies
- Liver Disease Diagnosis and Treatment
- Immune Response and Inflammation
- Immune Cell Function and Interaction
- Sarcoidosis and Beryllium Toxicity Research
- Health Systems, Economic Evaluations, Quality of Life
Kiel University
2016-2025
University Hospital Schleswig-Holstein
2016-2025
University of Lübeck
2016-2025
Clinical Research Center Kiel
2005-2025
Institute of Molecular Biology
2012-2024
University Medical Center
2004-2024
Universitäts Hautklinik Kiel
2008-2024
Goethe University Frankfurt
2023
German Inflammatory Bowel Diseases Study Group
2023
Marqués de Valdecilla University Hospital
2023
The discovery of a series genetic and serological markers associated with disease susceptibility phenotype in inflammatory bowel has led to the prospect an integrated classification system involving clinical, parameters. Working Party reviewed current clinical systems Crohn’s disease, ulcerative colitis indeterminate colitis, provided recommendations for practice. Progress respect integrating been examined detail, implications are discussed. While is not proposed use at present, introduction...
Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the of tofacitinib and maintenance therapy.
In this article we provide a contemporary overview of available clinical data on certolizumab pegol, pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises uniquely small protein, and its emerging role as therapy for Crohn's disease (CD). The results from comprehensive trial program suggest pegol offers rapid sustained remission moderate to severe CD. Certolizumab is an effective well-tolerated both in patients who have already received biologics are anti-TNF naïve. Benefits...
In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown.
Certolizumab pegol is a pegylated humanized Fab' fragment with high binding affinity for tumor necrosis factor alpha that does not induce apoptosis of T cells or monocytes.In our randomized, double-blind, placebo-controlled trial, we evaluated the efficacy certolizumab maintenance therapy in adults moderate-to-severe Crohn's disease. As induction therapy, 400 mg was administered subcutaneously at weeks 0, 2, and 4. Patients clinical response (defined as reduction least 100 from baseline...
Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue.We conducted two controlled trials to evaluate natalizumab as induction maintenance therapy in patients with active Crohn's disease. In the first trial, 905 were randomly assigned receive 300 mg of or placebo at weeks 0, 4, 8. The primary outcome was response, defined by decrease Disease Activity Index (CDAI) score least 70 points, week 10. second 339 who had...
SUMMARY The perpetuation of inflammation in ulcerative colitis and Crohn's disease may be regulated part by an increased secretion proinflammatory cytokines due to either appropriate response initial stimulating agents, and/or impaired down-regulalion cylokine secretion. aim this study was determine the patterns tumour necrosis factor-alpha (TNF-α), IL-6 IL-1β, from isolated lamina propria mononuclear cells (LPMNC) colonic biopsies patients with untreated or disease. LPMNC isoiated involved...
Expression of pro-inflammatory cytokines is increased in the intestinal lamina propria patients with inflammatory bowel disease (IBD). Nuclear factor kappa B (NF B) controls transcription inflammation genes. On activation, NF rapidly released from its cytoplasmic inhibitor (I B), transmigrates into nucleus, and binds to DNA response elements gene promoter regions.To investigate whether activation important IBD may be down-regulated by anti-inflammatory treatment.Activation was determined...